Virtual Group Visits for Type 2 Diabetes
(VIDA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the effectiveness of virtual group visits for managing type 2 diabetes. One group of participants will have monthly online meetings to discuss their diabetes care, while another group will continue with their usual care routines. The trial seeks individuals with type 2 diabetes who have recently recorded a blood sugar level (A1C) higher than 8% and also have conditions like high blood pressure or high cholesterol. Participants should be patients at a participating clinic and able to communicate in English or Spanish. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What prior data suggests that virtual group visits are safe for managing type 2 diabetes?
Research shows that virtual group visits for managing type 2 diabetes are generally safe. A review of studies found no major safety issues with these visits. Patients handle them well, and no harmful effects have been reported. Similar studies confirm their safety, indicating that these virtual visits do not add any extra risks for participants.12345
Why are researchers excited about this trial?
Researchers are excited about virtual group visits for type 2 diabetes because they're exploring a new way to deliver care that goes beyond traditional in-person visits or solo video consultations. This method allows patients to connect with each other and healthcare providers in a virtual setting, potentially enhancing support and motivation through shared experiences. Additionally, it offers a convenient and accessible option for patients who might face barriers to attending regular face-to-face appointments, helping them manage their condition more effectively.
What evidence suggests that virtual group visits are effective for type 2 diabetes?
This trial will compare Virtual Group Visits with Usual Care for managing type 2 diabetes. Studies have shown that virtual care can greatly improve health outcomes for people with type 2 diabetes. Research indicates that online group visits can effectively lower hemoglobin A1c levels, an important measure of long-term blood sugar control. Additionally, these visits can help reduce diabetes distress, the emotional stress affecting diabetes management. By connecting patients online, group visits offer support and shared learning, leading to better diabetes management. Early findings suggest that virtual group appointments are a promising way to provide care for chronic conditions like type 2 diabetes.13567
Who Is on the Research Team?
Arshiya Baig, MD
Principal Investigator
University of Chicago
Are You a Good Fit for This Trial?
This trial is for adults over 18 with type 2 diabetes and an A1C level above 8%, who also have a cardiovascular condition like high blood pressure, heart disease, or obesity. Participants must be from certain clinics, speak English or Spanish, and their primary care doctor must agree to their involvement.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants attend 6 monthly virtual group visits hosted by ACCESS or Advocate research staff
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Virtual Group Visit
Virtual Group Visit is already approved in United States for the following indications:
- Type 2 Diabetes Mellitus (T2DM)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Chicago
Lead Sponsor
Wake Forest University Health Sciences
Collaborator
ACCESS Community Health Network
Collaborator
Advocate Health Care
Collaborator
National Institute on Minority Health and Health Disparities (NIMHD)
Collaborator
Midwest Clinicians' Network
Collaborator